comparemela.com

Latest Breaking News On - Prnewswire cantargia - Page 3 : comparemela.com

Cantargia AB: Cantargia s CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022

Strongly supports therapeutic potential in one of CAN10's lead indications LUND, Sweden, Nov. 8, 2022 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported new

United statesPrnewswire cantargiaHeinrich heine university hiller research centerNasdaq stockholmSystemic sclerosisRelated disordersPreclinical models

Cantargia s CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2

(Nasdaq Stockholm: CANTA) today reported new preclinical data demonstrating positive effects of the.

United statesPrnewswire cantargiaHeinrich heine university hiller research centerNasdaq stockholmSystemic sclerosisRelated disordersBasic sciencedatePreclinical models

Cantargia presents new data at SITC 2022 supporting nadunolimab s promising antitumor clinical efficacy

LUND, Sweden, Nov. 7, 2022 /PRNewswire/ Cantargia (Cantargia AB; NASDAQ Stockholm: CANTA) today reported.

United statesCamilla rydberg millrudPrnewswire cantargiaPancreatic cancer action network panPancreatic cancer action networkImmune monitoringNovel technologiesabstractCamilla rydbergNasdaq stockholm

Cantargia AB: Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies

LUND, Sweden, Oct. 14, 2022 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today announced that the clinical trials CAPAFOUR and CESTAFOUR have enrolled enough patients to

Prnewswire cantargiaNasdaq stockholm

Cantargia AB: Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Keytruda and chemotherapy

LUND, Sweden, Sept. 22, 2022 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq: CANTA) (Stockholm: CANTA) today reported that the first patient has been treated in a new arm of the phase Ib clinical

Prnewswire cantargiaNasdaq stockholm

vimarsana © 2020. All Rights Reserved.